TX-FLUENCE
Fluence by OSRAM (Fluence), a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and agriculture production, announced today it is expanding its presence in the Emsland region of Germany through partnerships with growers and other horticulture specialists operating out of Papenburg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200124005109/en/
Given Papenburg’s decades-long history of attracting horticulture experts, Fluence’s innovative lighting solutions for horticulture are a natural fit for the region’s tomato, cucumber, leafy greens and herb growers.
Forging connections with Papenburg’s horticultural leaders
Elektro Evers , an engineering firm specializing in greenhouse technology, is Fluence’s exclusive systems integrator in the Papenburg region. Elektro Evers assists customers with installing, integrating and maintaining Fluence’s horticulture lighting systems. The company’s managing director, Norbert Bröring, says Fluence’s partnership is well-suited for the region.
“We are excited to collaborate with Fluence and bring the team’s deep horticulture lighting expertise to Papenburg’s growers,” Bröring said. “As an extension of German lighting innovator OSRAM, we know we’ve found the right partner in Fluence. Together, our advanced solutions will empower customers to cultivate plants under optimal conditions while mitigating energy demands.”
Papenburg’s Gartenbauzentrale —a 100-hectare food cooperative representing 49 family farms—recommends Fluence’s LED solutions to help members produce high-quality, consistent herbs and vegetables throughout the year. The energy savings resulting from LED use also enables Gartenbauzentrale members to apply for EU funding granted for resource conservation.
“Our members seek the most innovative, reliable technology for their farms,” said Marco Lüpken, head of controlling for Gartenbauzentrale. “High and consistent product quality as well as year-round predictable yields are key in our business. Fluence’s precise, high-intensity lighting solutions enable our growers to meet and exceed their growth goals efficiently with better-tasting plants.”
Investing in advanced technology: Greenhouse growers capitalize on LEDs
Friedrich Schulz’s 5.5 hectare farm—which grows herbs year-round in addition to lettuce, peppers and chives—utilizes VYPR 2p fixtures with PhysioSpec Greenhouse spectra across 3,000 square meters of lettuce crop.
“Switching from high pressure sodium lights to Fluence’s LED lights doubled our light intensity, leading to faster, more efficient grow cycles,” Schulz said. “The red lettuce grown under Fluence’s technology produced enhanced coloration within the first week alone. Fluence lighting achieves larger, higher quality yields while also keeping us energy efficient.”
For Reiner Borrmann, leveraging VYPR 2p lights with his basil crop yielded more flavorful, intense-tasting basil after replacing his greenhouse’s HPS lighting fixtures. Borrmann’s farm includes 4 hectares of greenhouse space.
“The energy efficiency allows us to grow more compact crops in less time, and the lights help us observe the plants’ natural colors,” Borrmann said.
Fluence’s general manager of EMEA, Timo Bongartz, said that implementing new LED systems is a decisive factor for a grower’s economic success.
“We are delighted to become an integral part of Papenburg’s cultivation ecosystem to enable growers to succeed in an extremely competitive environment,” Bongartz said. “With our horticulture lighting solutions, they are producing higher- and better-quality yields in less time while garnering significant energy savings. We’re delighted to nurture these partnerships through continued collaboration in the region.”
For more information on Fluence and its solutions for commercial agriculture, visit www.fluence.science .
About Fluence by OSRAM
Fluence Bioengineering, Inc., a wholly-owned subsidiary of OSRAM , creates the most powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is the leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are based in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. For more information about Fluence, visit https://fluence.science .
View source version on businesswire.com: https://www.businesswire.com/news/home/20200124005109/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)9.1.2026 13:00:00 CET | Press release
Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), today announced that the companies have entered into an option and license agreement designed to enable the structured evaluation of bispecific antibody-drug conjugate (BsADC) programs to further advance the development of dual-payload bispecific antibody-drug conjugates (BsAD2Cs). The agreement grants Acepodia an option to obtain an exclusive worldwide license from Biocytogen for two BsADC programs. Under the terms of the agreement, Biocytogen is eligible to receive an upfront option fee and, upon Acepodia’s exercise of the option, additional payments including option exercise fees, development, regulatory, and commercial milestone payments, as well as royalties on future product sales. The financial terms of the agreem
Blockstream Capital Partners Announces Strategic Acquisition of Derivatives Trading Team from Numeus Group, Leveraging Strategic Partnership with Komainu9.1.2026 11:08:00 CET | Press release
Blockstream Capital Partners (“BCP”) today announced that it has entered into a strategic agreement to acquire a division within Numeus Group’s digital asset trading and investment business. The transaction includes the absorption of select Bitcoin focused trading strategies with a focus on yield generation as well as a ten person derivatives trading team led by Chief Investment Officer Deepak Gulati, a specialist in volatility and derivatives markets. Deepak Gulati, appointed Co-Chief Investment Officer of Blockstream Capital Management alongside Rodrigo Rodriguez, previously served as Global Head of Proprietary Trading at JPMorgan, before founding Argentiere Capital, a multibillion-dollar volatility-focused hedge fund. With a thesis that derivatives would drive Bitcoin and digital asset market maturity, he co-founded Numeus Group in 2021 to develop institutional-grade trading, risk management and market-structure capabilities. Komainu, an existing BCP strategic investment, has played
Autel Unveils Strategic Shift at CES 2026: Building the AI-Powered Infrastructure of Future Cities9.1.2026 10:44:00 CET | Press release
At the Consumer Electronics Show (CES), Autel Energy is presenting its latest AI-driven smart hardware and software systems for the future of intelligent urban operations. This year’s showcase highlights Autel’s shift from AI concept validation to scenario-based engineering deployment, emphasizing closed-loop execution across real-world infrastructure. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260101511436/en/ Autel Energy New Product Debut at CES 2026 Focusing on two key domains — Smart Energy and Smart Inspection — the company is unveiling a range of new products. In Smart Energy, Autel is introducing V2G (Vehicle-to-Grid) AC charger for homes and DC charging solution for fleets, strengthening its multi-tier energy touchpoint strategy from households to commercial operations. Live demonstrations at the booth will feature a smart charging robot showcasing automated plug-in capabilities. In Smart Inspection, Autel will
Allianz and Anthropic Forge Global Partnership to Advance Responsible AI in Insurance9.1.2026 10:00:00 CET | Press release
Anthropic’s safety-first AI meets Allianz's dedication to customer centricity, stakeholder trust, and regulatory excellenceThree focus areas of the partnership: workforce empowerment, operations automation through agentic AI, and regulatory compliance Allianz SE and Anthropic today announced a global partnership to accelerate the adoption of responsible Artificial Intelligence (AI) at Allianz. The collaboration centers on three transformative projects within Allianz Group designed to empower Allianz employees and accelerate operations, while setting new benchmarks for accuracy. “With this partnership, Allianz is taking a decisive step to address critical AI challenges in insurance. Anthropic’s focus on safety and transparency complements our strong dedication to customer excellence and stakeholder trust. Together, we are building solutions that prioritize what matters most to our customers while setting new standards for innovation and resilience,” said Oliver Bäte, CEO of Allianz SE.
MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis9.1.2026 07:00:00 CET | Press release
MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment of inflammatory bowel diseases (IBD) STARFISH-UC Phase 2b trial is designed to confirm MH002’s early efficacy signals and favorable safety observed in Phase 2a studies MRM Health NV, a clinical-stage biopharmaceutical company pioneering microbiome-based therapeutics for inflammatory diseases and immune-oncology, today announced that the U.S. Food and Drug Administration (FDA) has granted clearance of its Investigational New Drug (IND) application for its lead program MH002. This enables the initiation of the STARFISH-UC Phase 2b clinical trial in patients with mild-to-moderate ulcerative colitis, marking a significant step forward in the development of next-generation therapies for inflammatory bowel diseases (IBD). About the STARFISH-UC Phase 2b Trial The STARFISH-UC trial is a randomized, double-blind,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
